sorafenib

0:02:57

Sorafenib as SOC maintenance after allo-transplant in FLT3+ AML

0:04:06

BTTC Everolimus/Sorafenib Study

0:05:41

Phase II trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia

0:04:40

DECISION Trial: Support for Sorafenib

0:05:16

Practical Views on Sorafenib

0:01:21

Dr. Abou-Alfa on Sorafenib Plus Doxorubicin in Patients With HCC

0:03:05

IMbrave150: updated data on atezo plus bev versus sorafenib in HCC

0:01:27

Dr. Pinato on Study of Sorafenib in Pretreated Patients With HCC

0:03:27

Sorafenib vs placebo in treatment-naïve FLT3-ITD AML

0:00:37

An Expert's Insights on Combination TACE Plus Sorafenib for Intermediate HCC

0:01:10

Real Life Analysis Shows Regorafenib Improves Survival Upon Progression on Sorafenib in HCC

0:16:47

¿EXISTE ALGÚN TRATAMIENTO SISTÉMICO ALTERNATIVO AL SORAFENIB EN EL HEPATOCARCINOMA

0:01:38

Results of TRIAS 2009 trial of sorafenib with topotecan in ovarian cancer

0:01:01

Relationship Between OCT1 Expression and Poor Response to Sorafenib in HCC

0:01:33

Adverse Events Inform Treatment Decisions in HCC for Frontline Lenvatinib Versus Sorafenib

0:01:21

Dr. Montal on Molecular Predictors of Recurrence With Adjuvant Sorafenib in HCC

0:02:28

NRG/RTOG 1112: sorafenib vs SBRT followed by sorafenib in HCC

0:28:11

Hepatocellular Carcinoma - Molecular Approaches to Treatment

0:04:33

Results from a Phase III study of sorafenib and SBRT for hepatocellular carcinoma

0:04:37

Options Following Sorafenib in HCC

0:02:22

Regorafenib and PD-1 inhibitor for a Sorafenib-Refractory HCC patient - Video abstract [ID 284092]

0:01:15

Dr. Vaishampayan on the Safety of Tivozanib Versus Sorafenib in RCC

0:03:18

Rationale and study design of a Phase III study of sorafenib and SBRT for hepatocellular carcinoma

0:01:00

Richard Finn, MD, considers the effectiveness of sorafenib in newly diagnosed HCC